Veylinx Study Reveals Increasing Demand for Multi-Purpose Sunscreens
A new study from leading behavioral research firm Veylinx reveals consumer SPF preferences, emerging skincare trends, and how much consumers are willing to pay for sunscreen—a behavior driven by a growing fear of sun exposure.
Veylinx surveyed consumers on their preferences and willingness to pay for basic versus enhanced versions of popular sunscreen brands.
The findings highlight growing consumer awareness of sunscreen benefits and a growing demand for sunscreen products that go beyond basic UV protection. Demand for products with anti-aging benefits grew 49%, followed by moisturizers up 33%, and products containing vitamin C up 23%.
The study shows that 38% of people never feel completely at ease in the sun, 60% report burning easily, and 41% worry about skin damage. 30% of respondents apply sunscreen every day during the summer, while another 21% apply five to six times a week, while only 27% use sunscreen year-round. 65% of consumers prefer sunscreens with an SPF of 40 or higher.
The study also compared brands, with the overall ranking showing Neutrogena at the top with 41%, followed by Cerave 38%, Coppertone 35%, Olay 33%, Supergoop 17%, and Target's Up & Up brand 14%.
Supergoop, which has moisturizing properties, has the highest price, while Supergoop, Cerave, and Olay's anti-aging products have seen the largest increase in demand over basic versions.
Notably, 27% of consumers choose reef-safe sunscreens, and consumers interested in these products are willing to pay 14% more, making "reef-safe" a potential important revenue driver for brands. While this suggests consumers are more concerned about ocean protection, only 16% choose to use sustainable packaging.
2026-08-26
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
U.S. Delays Mandatory GRAS Notification Proposal, Pushing Food-Additive Overhaul to Year-End
-
关于将4-amino-1-boc-piperidine、tert-buty 4-aminopiperidine-1-carboxylate产品列入《ECHEMI平台禁限售商品目录》的公告 Announcement on Including 4-amino-1-boc-piperidine and tert-buty 4-aminopiperidine-1-carboxylate in the Announcement on the List of Prohibited Sales of Prohibited and Controlled Items on ECHEMI
-
U.S. Exempts Critical Chemical Manufacturers from Emissions Rules for Two Years
-
China Releases 15th Five-Year Carbon-Peaking Action Plan, Pushing Coal Chemicals into a Mandatory Low-Carbon Upgrade Cycle
-
关于加强防范钓鱼邮件的通知 Notification on Strengthening Anti-Phishing Measures
-
Bayer and Syngenta Score Consecutive Regulatory and Legal Wins in the U.S.
-
South Korea Expands Mandatory GMO Labeling to Highly Processed Foods
-
Vera’s New Kidney Drug Wins FDA Approval, Carrying a $425,000 Annual Price
-
FDA Tightens the Solvent Side of Natural Color Production
-
India’s Tariff Cuts Could Lower Agrochemical Costs
Recommend Reading
-
FSANZ Moves Toward Approval of Insect-Resistant Corn COR121
-
Thymol Gel Wins EPA Approval for Beekeepers
-
关于进一步规范化学品信息发布、加强全球管制目录宣导的公告 Announcement on Further Standardizing the Release of Chemical Information and Strengthening Public Awareness of Global Control Lists
-
FDA Names Veteran Oncology Regulator Pazdur as Director of Drug Review Center
-
FDA Slows Two Natural Color Approvals, but the Additive Shift Is Still Moving
-
Since December, China’s phenol market has accelerated its downward trend and is now fluctuating at low levels
-
MTBE Market Conditions Remain Weak
-
Uses of Sodium Acetate Trihydrate
-
Key Reactions and Uses of Allene
-
Weak Demand Pressures Adipic Acid Prices in China